TelyRx Holdings (TSX:TELY) Ending Cash Position: C$37.04 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:TELY TelyRx Holdings Inc TSX:TELY
12 GF Score
Price C$2.60
! 1 Warning Sign
View Full Analysis

What is TelyRx Holdings Ending Cash Position?

TelyRx Holdings TSX:TELY +13.04% 12 Ending Cash Position is C$37.04 Mil as of Mar. 2026. GuruFocus rates TSX:TELY with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

TelyRx Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 was C$37.04 Mil.

TelyRx Holdings's quarterly Ending Cash Position increased from Sep. 2025 (C$0.00 Mil) to Dec. 2025 (C$4.12 Mil) and increased from Dec. 2025 (C$4.12 Mil) to Mar. 2026 (C$37.04 Mil).

TelyRx Holdings's annual Ending Cash Position increased from Dec. 2023 (C$0.59 Mil) to Dec. 2024 (C$4.72 Mil) but then declined from Dec. 2024 (C$4.72 Mil) to Dec. 2025 (C$4.12 Mil).

TelyRx Holdings Ending Cash Position Related Terms

TelyRx Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for TelyRx Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TelyRx Holdings Ending Cash Position Chart

TelyRx Holdings Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
0.59 4.72 4.12

TelyRx Holdings Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial 4.72 4.35 0.00 4.12 37.04
TSX:TELY
12GF Score
TelyRx Holdings Inc TSX:TELY
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TelyRx Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TelyRx Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.571+-0.449
=4.12

TelyRx Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.1+32.94
=37.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of C$37.04 Mil mean?
TelyRx Holdings (TSX:TELY) has a Ending Cash Position of C$37.04 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TelyRx Holdings and its competitors.
Is TelyRx Holdings' Ending Cash Position too high?
TelyRx Holdings' current Ending Cash Position is C$37.04 Mil. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' Ending Cash Position compare to competitors?
TelyRx Holdings' Ending Cash Position of C$37.04 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TelyRx Holdings and its competitors. TelyRx Holdings's current Ending Cash Position is C$37.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TSX:TELY) has a current Ending Cash Position of C$37.04 Mil. The current Ending Cash Position is C$37.04 Mil. TelyRx Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For TelyRx Holdings (TSX:TELY), the current Ending Cash Position is C$37.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TelyRx Holdings Business Description

Address 24761 US Highway 19 North, Clearwater, FL, USA, 33763
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score

Get the complete analysis for TSX:TELY

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.60
Price